Ask HopeStage to review this study with me
Study ID: NCT03382639. We help you review the study, but cannot decide medical eligibility.
CompletedNCT03382639
3 Dose Levels of TAK-831 for schizophrenia
This study is completed in the United States, in Bulgaria, in Czechia, .... It is testing 3 Dose Levels of TAK-831 for schizophrenia.
SchizophreniaDrugFrom 18 Years to 60 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Bulgaria · 7 sites
- State Psychiatric Hospital - LovechLovechSite status: Not listed — confirm with the team
- State Psychiatric Hospital "Sv. Ivan Rilski", Novi IskarNovi IskarSite status: Not listed — confirm with the team
- UMHAT 'Dr. Georgi Stranski', EADPlevenSite status: Not listed — confirm with the team
- Medical Centre "Sv. Naum"SofiaSite status: Not listed — confirm with the team
- DCC "Sv. Vrach and Sv. Sv. Kuzma and Damyan", OODSofiaSite status: Not listed — confirm with the team
- DCC "Mladost M" - Varna, OODVarnaSite status: Not listed — confirm with the team
- Mental Health CenterVratsa EOODVratsaSite status: Not listed — confirm with the team
Czechia · 6 sites
- Narodni ustav dusevniho zdraviKlecanySite status: Not listed — confirm with the team
- A-SHINE s.r.o.PilsenSite status: Not listed — confirm with the team
- CLINTRIAL s.r.o.PragueSite status: Not listed — confirm with the team
- PRAGTIS s.r.o.PragueSite status: Not listed — confirm with the team
- Vseobecna fakultni nemocnice v PrazePragueSite status: Not listed — confirm with the team
- MUDr. Simona Papezova s.r.o.PragueSite status: Not listed — confirm with the team
Germany · 4 sites
- Zentralinstitut fuer Seelische GesundheitMannheim, Baden-WurttembergSite status: Not listed — confirm with the team
- Studienzentrum NordwestWesterstede, Lower SaxonySite status: Not listed — confirm with the team
- Universitaetsklinikum Leipzig AoeRLeipzig, SaxonySite status: Not listed — confirm with the team
- Charite Universitaetsmedizin Berlin - Campus Charite MitteBerlinSite status: Not listed — confirm with the team
Italy · 5 sites
- Azienda Ospedaliero Universitaria Consorziale Policlinico di BariBariSite status: Not listed — confirm with the team
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)BresciaSite status: Not listed — confirm with the team
- Azienda Ospedaliera Universitaria- Universita degli Studi della Campania Luigi VanvitelliNaplesSite status: Not listed — confirm with the team
- Azienda Ospedaliera di PadovaPadovaSite status: Not listed — confirm with the team
- Azienda Ospedaliera Citta della Salute e della Scienza di TorinoTorinoSite status: Not listed — confirm with the team
Poland · 7 sites
- Przychodnia Srodmiescie Sp. z o. o.BydgoszczSite status: Not listed — confirm with the team
- NZOZ SyntoniaGdyniaSite status: Not listed — confirm with the team
- Care ClinicKatowiceSite status: Not listed — confirm with the team
- NZOZ Poradnia Zdrowia PsychicznegoKobierzyceSite status: Not listed — confirm with the team
- Centrum Medyczne PlejadyKrakowSite status: Not listed — confirm with the team
- Medycyna MilorzabLodzSite status: Not listed — confirm with the team
- Centrum Medyczne "Luxmed" Sp. z o.o.LublinSite status: Not listed — confirm with the team
Spain · 2 sites
- Hospital Clinic de BarcelonaBarcelonaSite status: Not listed — confirm with the team
- Hospital Universitario 12 de OctubreMadridSite status: Not listed — confirm with the team
Ukraine · 7 sites
- Regional Psychoneurological Hospital #3Ivano-FrankivskSite status: Not listed — confirm with the team
- CIH Kharkiv Regional Clinical Psychiatric Hospital #3KharkivSite status: Not listed — confirm with the team
- Kyiv CH on Railway Transport #2 of Branch Center of Healthcare Public Company Ukr RailwayKyivSite status: Not listed — confirm with the team
- CI Kirovograd RPH Male dept#11,Female dep#17 Donetsk NMUNove, KropyvnytskiySite status: Not listed — confirm with the team
- Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMUTernopilSite status: Not listed — confirm with the team
- Transcarpathian Regional Narcological DispensaryUzhhorodSite status: Not listed — confirm with the team
- Zhytomyr Regional Psychiatric Hospital #1Zarichany Vil.Site status: Not listed — confirm with the team
United States · 16 sites
- Collaborative Neuroscience Network, LLCGarden Grove, CaliforniaSite status: Not listed — confirm with the team
- Synergy Clinical Research CenterLemon Grove, CaliforniaSite status: Not listed — confirm with the team
- Semel Institute for Neuroscience and Human BehaviorLos Angeles, CaliforniaSite status: Not listed — confirm with the team
- Excell ResearchOceanside, CaliforniaSite status: Not listed — confirm with the team
- NRC Research InstituteOrange, CaliforniaSite status: Not listed — confirm with the team
- Artemis Institute for Clinical Research, LLCSan Diego, CaliforniaSite status: Not listed — confirm with the team
- Connecticut Mental Health Center - Yale UniversityNew Haven, ConnecticutSite status: Not listed — confirm with the team
- Atlanta Center for Medical ResearchAtlanta, GeorgiaSite status: Not listed — confirm with the team
- Augusta UniversityAugusta, GeorgiaSite status: Not listed — confirm with the team
- The Dr. Alan & Diane Breier Prevention and Recovery Center for Early PsychosisIndianapolis, IndianaSite status: Not listed — confirm with the team
- Center for Behavioral Health, LLCGaithersburg, MarylandSite status: Not listed — confirm with the team
- Cherry HealthGrand Rapids, MichiganSite status: Not listed — confirm with the team
- Manhattan Psychiatric CenterNew York, New YorkSite status: Not listed — confirm with the team
- Research Strategies of Memphis, LLCMemphis, TennesseeSite status: Not listed — confirm with the team
- Community Clinical Research, Inc.Austin, TexasSite status: Not listed — confirm with the team
- Core Clinical ResearchEverett, WashingtonSite status: Not listed — confirm with the team
Key information made simple
What is this study testing?
This study is testing whether Luvadaxistat may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive Luvadaxistat, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Bulgaria, in Czechia, and in Germany.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: January 4, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 256
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Bulgaria, Czechia, ...
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT03382639
- Official title
- A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT03382639. We help you review the study, but cannot decide medical eligibility.
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Luvadaxistat, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 60 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Neurocrine Biosciences, which appears to be a biotech company. Sponsor website: https://www.neurocrine.com. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01157351
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
This study is completed. It focuses on schizophrenia and currently lists study information in the United States.
CompletedEUCTR 2011-004790-90
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
CompletedEUCTR 2016-000061-23
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.